UNSPSC 51142042: Flupirtine maleate

This classification denotes an analgesic agent with the molecular structure C15H17FN4O2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 0VCI53PK4A chemically known as carbamic acid, (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)-, ethyl ester, (z)-2-butenedioate (1:1), but more commonly known as flupirtine maleate, which bears US NIH Compound Identifier 6435335. European Medicines Agency schedules Flupirtine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02234MIG.

UNSPSC 51142042 Flupirtine maleate is a Commodity code that represents a specific pharmaceutical product, but recent state and local solicitations tagged to this code show no actual procurement activity for flupirtine itself. Instead, the opportunities reveal a mismatch: Seminole County, Florida solicited naloxone and drug deactivation systems; the Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicited generic multi-source pharmaceuticals and over-the-counter products through authorized wholesalers. The actual procurement activity under this code segment involves naloxone products, OTC pharmaceuticals, and pharmacy benefit strategy development rather than the specific active pharmaceutical ingredient named in the commodity code itself. State and local buyers using this UNSPSC designation appear to be health departments, state health agencies, and cooperative purchasing alliances managing pharmaceutical supply chains and community health initiatives.

Activity is concentrated in the South and Upper Midwest, with documented recent solicitations in Florida, Texas, and Minnesota through early 2026. Seminole County's IFB (Solicitation IFB60459723LAS, due July 26, 2023, though posted June 30, 2026) seeks annual procurement of 1,900 naloxone units and 800 safe drug deactivation systems with quarterly deliveries to support community health. The Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) establishes multi-state contracts for generic pharmaceuticals and OTC products distributed across participating government facilities in Minnesota and Oregon, with awards effective July 1, 2026. The Texas HHS RFI (HHS0017013, posted April 3, 2026) gathers market intelligence on direct-to-manufacturer prescription fulfillment capacity rather than procuring a specific product. The code shows limited recent activity directly aligned with flupirtine procurement; vendors should verify whether opportunities tagged to this code actually require the specific commodity or whether buyers are using the code as a broad pharmaceutical category marker.